Akebia Therapeutics/AKBA
$1.40
--
1D1W1MYTD1YMAX
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Ticker
AKBA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
John Butler
Employees
167
Headquarters
Cambridge, United States
Website
akebia.com
AKBA Metrics
BasicAdvanced
$312M
Market cap
-
P/E ratio
-$0.28
EPS
0.84
Beta
-
Dividend rate
Price and volume
Market cap
$312M
Beta
0.84332
52-week high
$2.48
52-week low
$0.78
Average daily volume
4.9M
Financial strength
Current ratio
1.183
Quick ratio
1.026
Interest coverage (TTM)
-7.64%
Management effectiveness
Return on assets (TTM)
-17.37%
Return on investment (TTM)
-28.19%
Valuation
Price to revenue (TTM)
1.605
Growth
Revenue change (TTM)
-33.29%
Earnings per share change (TTM)
48.31%
3-year revenue growth
-12.91%
What the Analysts think about AKBA
Analyst Ratings
Majority rating from 3 analysts.
Price Targets
Average projection from 3 analysts.
High $6.00
Low $4.00
$1.40
Current price
$5.00
Average price target
AKBA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$56M
33.57%
Net income
$600K
-104.17%
Profit margin
1.06%
-103.09%
AKBA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.14
-$0.06
-$0.08
-
-
Expected
-$0.15
-$0.03
-$0.09
-$0.04
-$0.08
Surprise
-6.67%
140%
-5.88%
-
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for Akebia Therapeutics stock?
Akebia Therapeutics (AKBA) has a market cap of $312M as of May 09, 2024.
What is the P/E ratio for Akebia Therapeutics stock?
The price to earnings (P/E) ratio for Akebia Therapeutics (AKBA) stock is 0 as of May 09, 2024.
Does Akebia Therapeutics stock pay dividends?
No, Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders as of May 09, 2024.
When is the next Akebia Therapeutics dividend payment date?
Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders.
What is the beta indicator for Akebia Therapeutics?
Akebia Therapeutics (AKBA) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the Akebia Therapeutics stock price target?
The target price for Akebia Therapeutics (AKBA) stock is $5, which is 257.14% above the current price of $1.4. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Akebia Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.